Overexpression of SETDB1 is associated with aggressive phenotypes in cancers, such as breast, colon, liver, lung, and myeloid leukemia, where its activity promotes rapid cell growth, proliferation, and immune evasion.15 Here, SETDB1 is linked to cancer.